Your browser doesn't support javascript.
loading
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center.
Sakuraba, Atsushi; Keyashian, Kian; Correia, Chase; Melek, John; Cohen, Russell D; Hanauer, Stephen B; Rubin, David T.
Affiliation
  • Sakuraba A; Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois 60637, USA. asakurab@medicine.bsd.uchicago.edu
Inflamm Bowel Dis ; 19(3): 621-6, 2013 Mar.
Article in En | MEDLINE | ID: mdl-23429449
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Crohn Disease / Antibodies, Monoclonal, Humanized / Immunosuppressive Agents Type of study: Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Inflamm Bowel Dis Journal subject: GASTROENTEROLOGIA Year: 2013 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Crohn Disease / Antibodies, Monoclonal, Humanized / Immunosuppressive Agents Type of study: Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Inflamm Bowel Dis Journal subject: GASTROENTEROLOGIA Year: 2013 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido